Popular diabetes and weight drug reduced people’s desire to drink alcohol.
The results, from the first clinical trial of this sort, suggest that semaglutide could also be promising as a treatment for problematic alcohol consumption. The semaglutide is sold as ozempic and wagova.
Some people reported that this drug family, called GLP-1 agonists, limits not only the desire to eat, but in addition to drink alcohol and smoking. Data from mice, rats and inhuman chief confirm this. But there was no clear evidence of individuals.
The latest study included 48 adults, all of which had an alcohol consumption. None of the participants searched for treatment of a disorder, which, as estimated, influenced about 29 percent of adults in the United States in some unspecified time in the future in life. Each volunteer was randomly assigned to receive weekly semaglutide injections or placebo.
At the starting and at the end of the nine -week treatment period, the participants entered the laboratory and offered a preferred alcoholic drink. After receiving the semaglutide, people He drank less alcoholClinical psychologist Christian Hendershot from the University of Southern California in Los Angeles, and colleagues report on February 12 during a laboratory drinking session at the end of the experiment, individuals who received Placebo drank on average lower than 60 grams of alcohol; People at semaglutede drank about half – just over 30 grams. The standard can of 12 ounces beer has about 14 grams of alcohol.
What’s more, in the second half of the experiment, people at semaglutede reported drinking about 30 percent less beverages on the days they drank compared to the basic drinking habits. People on the placebo dropped the drink on drinking days only Smidge. This discovery indicates that semaglutide can reduce the amount of alcohol that folks drink, even when it doesn’t stop them from completely drinking.
Hendershot says the results seem promising. Still, “it’s best to carefully watch these numbers.” Greater tests are needed in longer periods to confirm and explain the impact of GLP-1 drugs on the use by people alcohol and other harmful substances, including tobacco and opioids.
